디티앤씨알오
383930KOSDAQ자연과학 및 공학 연구개발업66.8 / 100
Reference Date: 2026-04-13
Company InformationBased on 2025 Annual Report
Business Overview
DT&CR is a Full-Service CRO providing non-clinical and clinical trial services across pharmaceuticals, medical devices, and health functional foods, offering integrated solutions from early-stage drug development to FDA approval. In 2025, revenue increased by 32.7% year-over-year to 47.7 billion won, driven by specialized services such as the expanded PK/PD center, which scientifically analyzes drug candidate characteristics.
Number of Employees
314people
Average Salary
47.4M KRW
Score Calculation Basis
Detailed Financial Score
Half of industry avg (excellent)
Well below industry avg
7.2x industry avg (risky)
Avg ▲34.0% (2-year basis)
Avg ▲28.0% (2-year basis)
Avg ROE -19.9% (improving, 3yr)
Detailed News Sentiment
- Positive디티앤씨알오 "진통·소염 복합제 디지털 활용 임상 성공…국내 최초...
디티앤씨알오가 진통·소염 복합제 임상 3상을 성공적으로 수행하여 요통 적응증 추가 승인 및 eCOA 활용 허가 획득이라는 국내 최초 성과를 달성했습니다.
- Positive디티앤씨알오 "요통 적응증·eCOA 적용 국내 첫 성과"
디티앤씨알오가 진통·소염 복합제 임상 수행을 통해 요통 적응증 및 eCOA 적용 국내 첫 성과를 달성하며 임상적 차별성을 확보했습니다.
- Positive디티앤씨알오, 근감소증 신약개발기업 바이오바이츠 신약개발 전주기...
디티앤씨알오가 근감소증 신약개발 전문기업 바이오바이츠와 신약개발 전주기 협력을 위한 업무협약(MOU)을 체결했습니다.
Detailed Momentum
52w lower range (26%)
1m +19.09% (strong rise)
Volume surge
Detailed Disclosure
- Neutral정기주주총회결과2026-03-30
- Neutral감사보고서제출2026-03-20
- Neutral사업보고서 (2025.12)2026-03-20
